{
    "clinical_study": {
        "@rank": "95672", 
        "arm_group": [
            {
                "arm_group_label": "Fluticasone, cream", 
                "arm_group_type": "Experimental", 
                "description": "fluticasone propionate (FP) cream of 0.05%. The vehicle is:Base PFCO/W, Propyleneglycol and Water conservant."
            }, 
            {
                "arm_group_label": "Placebo, cream", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle cream is composed by Base PFCO/W, Propyleneglycol and Water conservant."
            }
        ], 
        "brief_summary": {
            "textblock": "The relapsing nature of atopic dermatitis (AD) presents a challenge for its long-term\n      treatment. Efficacy and safety of corticosteroids have been proven in the acute treatment of\n      AD, but not its efficacy and security to reduce or prevent relapses.\n\n      Objectives To investigate long-term management (16 weeks) of AD with fluticasone propionate\n      (FP) 0,05% cream twice weekly in addition to an emollient (vehicle) after stabilization of\n      an acute flare of AD with FP cream."
        }, 
        "brief_title": "Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Dermatitis, Atopic", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients 2-10 years of age with a history of mild to moderate AD will be eligible for this\n      multicentre, randomized, double-blind, controlled study if they present an acute flare of AD\n      (<30% affected body surface area; no head). After successful treatment of the flare in an\n      acute phase, patients will receive either, FP twice weekly plus vehicle or vehicle alone\n      over a 16-week maintenance phase. The primary study end point will be probability of a\n      relapse of AD occurring. We will conduct survivor analysis of results."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children, aged 2 to 10 years, with mild or moderate acute flare of AD (SCORAD up to\n             50) and no treatment for this episode of AD.\n\n          -  written informed consent to patients' parents.\n\n        Exclusion Criteria:\n\n          -  >30% of affected body surface area AD.\n\n          -  Head affected.\n\n          -  Fluticasone o vehicle allergy.\n\n          -  Patients with any medical condition for which topical corticosteroids were\n             contraindicated\n\n          -  Patients with other dermatological conditions that may have prevented accurate\n             assessment of AD\n\n          -  Patients with receiving any concomitant medications that might have affected the\n             study's outcome.\n\n          -  Other medical history that could interfere with the evaluation of study treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "10 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772056", 
            "org_study_id": "FLUTIDANENES08", 
            "secondary_id": [
                "EC08/00004", 
                "2008-005360-14"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Fluticasone, cream", 
                "description": "Experimental Group: on treatment with twice weekly on consecutive days FP cream of 0.05% for 16 weeks or at relapse", 
                "intervention_name": "Fluticasone, cream", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo, cream", 
                "description": "Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.", 
                "intervention_name": "Placebo,", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fluticasone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dermatitis, Atopic", 
            "Randomized Controlled Trial", 
            "Child", 
            "Fluticasone", 
            "Preventive therapy"
        ], 
        "lastchanged_date": "January 20, 2013", 
        "location": [
            {
                "contact": {
                    "email": "vpalop@hospital-ribera.com", 
                    "last_name": "Vicente Palop Larrea, PhD MD", 
                    "phone": "962458190"
                }, 
                "facility": {
                    "address": {
                        "city": "Alzira", 
                        "country": "Spain", 
                        "state": "Valencia", 
                        "zip": "46600"
                    }, 
                    "name": "Departamento de Salud Valencia-La Ribera"
                }, 
                "investigator": [
                    {
                        "last_name": "Vicente Palop Larrea, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Juan C Julia Benito, PhD MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bernalte_ale@gva.es", 
                    "last_name": "Bernalte"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46014"
                    }, 
                    "name": "Departamento de Salud Valencia - Hospital General"
                }, 
                "investigator": [
                    {
                        "last_name": "Antonio Martorell Aragones, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Juan C Cerda Mir, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Inocencia Martinez Mir, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Alejandro Bernalte Sese, Pharmacist", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "M\u00aa Isabel Febrer Bosch, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Francisco J Morales Olivas, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Cristina Morales Carpi, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ana B Ferrer Bautista, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "M\u00aa Esther Apolinar Valiente, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "M\u00aa Antonia Beltran Marques, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sandra Solaz Barrios, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "M\u00aa Victoria Planelles Cantarino, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Pedro Polo Marti, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Victoria E Garcia Martinez, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Dolores Marmaneu Laguia, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "M\u00aa Mercedes Loriente Tur, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Olga Pe\u00f1alver Giner, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "M\u00aa Bego\u00f1a Rodriguez Gracia, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "M\u00aa Jose Tejedor Sanz, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "M\u00aa Enriqueta Burches Greus, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "M\u00aa Carmen Tordera Marti, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Teresa Margarit Vercher, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Inmaculada Llosa Cortes, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Trinidad Alvarez de Laviada Mulero, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Emilio J Ferriols Gil, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ruben R Felix Toledo, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Natividad Pons Fernandez, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Elena Rubio Gomis, PhD MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "laura_arandagrau@yahoo.es", 
                    "last_name": "Laura Aranda Grau, PhD MD", 
                    "phone": "34962761208"
                }, 
                "contact_backup": {
                    "email": "irenmed@yahoo.es", 
                    "last_name": "Irene Alvarez Gonzalez, MD", 
                    "phone": "34962761208"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46015"
                    }, 
                    "name": "Departamento de Salud Valencia-Arnau-Lliria"
                }, 
                "investigator": [
                    {
                        "last_name": "Antonio M Abella Bazataqui, PhD MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Irene Alvarez Gonzalez, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Laura Aranda Grau, PhD MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "paalcri@hotmail.com", 
                    "last_name": "Rosario Carpi Lobaton, MD", 
                    "phone": "34961851461"
                }, 
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46010"
                    }, 
                    "name": "Departamento Valencia-Clinic-Malvarrosa"
                }, 
                "investigator": [
                    {
                        "last_name": "Rosario Carpi Lobaton, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Francisco J Fernandez Ros, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomised Controlled, Double Blind Trial of Topical Twice Weekly Fluticasone Propionate Maintenance Treatment to Reduce Risk of Relapse in Mild or Moderate Atopic Dermatitis in Children", 
        "overall_contact": {
            "email": "bernalte_ale@gva.es", 
            "last_name": "Alejandro Bernalte, Pharmacist", 
            "phone": "34961972000", 
            "phone_ext": "52185"
        }, 
        "overall_contact_backup": {
            "email": "macia.arancha@experior.es", 
            "last_name": "Arancha Macia", 
            "phone": "34962458190"
        }, 
        "overall_official": {
            "affiliation": "Consorcio Hospital General Universitario de Valencia y Universidad de Valencia", 
            "last_name": "Elena Rubio Gomis, PhD MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary study end point will be probability of a relapse of AD occurring (the relapse rate of AD).", 
            "measure": "Relapse in Atopic Dermatitis (AD).", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772056"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Valencia", 
            "investigator_full_name": "Elena Rubio Gomis", 
            "investigator_title": "Professor of Pharmacology. Clinical Pharmacology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The number of days from start of the Fluticasone propionate treatment in Double-blind Maintenance Phase (DMP) until AD relapse.", 
                "measure": "Time to relapse", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "The proportion of children experiencing a relapse of AD during DMP.", 
                "measure": "Incidence of relapse", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Severity of AD was scored by means of the modified Scoring of Atopic Dermatitis system (SCORAD).The difference of SCORAD intensity between initial values, Open-label Stabilization Phase (OSP), and end values (end of DMP)", 
                "measure": "severity of the relapse", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "Safety was assessed by monitoring adverse events and adverse effects throughout the study.", 
                "measure": "Adverse events and adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "22 weeks"
            }, 
            {
                "description": "To describe the therapeutic compliance by means of the control of the drug used.", 
                "measure": "Therapeutic compliance", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }
        ], 
        "source": "University of Valencia", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Instituto de Salud Carlos III", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Elena Rubio Gomis", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}